GH Fragment 176-191
Fat LossGH C-terminal fragment / researchExperimental
C-terminal fragment of human GH studied for lipolysis. Closely related to AOD-9604. Not FDA-approved. WADA S2 (GH fragments).
For research use only.
Key Facts
- CAS
- 66004-57-7
- Molecular Weight (MW)
- ≈1729 g/mol
- Half-life
- Short (minutes–hours; animal PK)
- Unit
- mcg
- Administration Route
- Subcutaneous (research contexts)
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- Adipose lipolytic pathways
Overview
C-terminal fragment of human GH studied for lipolysis. Closely related to AOD-9604. Not FDA-approved. WADA S2 (GH fragments).
Protocol
- Dosage Range
- Not established for human therapy
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous (research contexts)
- Reconstitution Guide
- —
Science
Mechanism of Action
C-terminal GH residues investigated for fat-mobilizing effects without the full GH receptor growth program. Human evidence for meaningful fat loss is weak.
Targets
Adipose lipolytic pathways
Studies
- hGH 176-191 / AOD9604 literature— Journal/year not available
Benefits
GH-fragment pharmacology research
Potential Side Effects
- Injection reactions
- Uncertain efficacy
References
- PMID 17026461External link · Year —
- WADA Prohibited List 2026External link · Year —